Trial Profile
Efficacy and safety of multiple-dose oritavancin therapy for treatment of complicated infectious diseases.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Nov 2017
Price :
$35
*
At a glance
- Drugs Oritavancin (Primary)
- Indications Bacteraemia; Skin and soft tissue infections
- Focus Therapeutic Use
- 20 Nov 2017 New trial record
- 09 Nov 2017 Results assessing efficacy and safety of multiple-dose oritavancin therapy for treatment of complicated infectious diseases, were published in the Pharmacotherapy.